富马酸替诺福韦二吡呋酯对HBV感染孕妇肾功能和胎儿生长发育的安全性研究*

doi:10.3969/j.issn.1672-5069.2022.04.008

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (4): 484-487.doi: 10.3969/j.issn.1672-5069.2022.04.008

富马酸替诺福韦二吡呋酯对HBV感染孕妇肾功能和胎儿生长发育的安全性研究^*

熊霞鹂, 魏宏, 朱云霞, 段钟平

100069 北京市首都医科大学附属北京佑安医院肝病产科(熊霞鹂,魏宏,朱云霞);肝病内科(段钟平)

收稿日期:2022-01-21 出版日期:2022-07-10 发布日期:2022-07-14
通讯作者: 段钟平,E-mail: duan@ccmu.edu.cn
作者简介:熊霞鹂,女,35岁,硕士研究生,主治医师。主要从事肝病产科诊断与治疗学研究。E-mail:xiongxiali2009@163.com
基金资助:
^*国家科技重大专项资金资助项目:“艾滋病和病毒性肝炎等重大传染病防治”科技重大专项(编号:2017ZX10201201-001-001)

Safety of tenofovir disoproxil fumarate in pregnant women with HBV infection: An observation on renal functions and fetal growths

Xiong Xiali, Wei Hong, Zhu Yunxia, et al

Department of Obstetrics and Liver Diseases, You'an Hospital, Capital Medical University, Beijing 100069, China

Received:2022-01-21 Online:2022-07-10 Published:2022-07-14

摘要/Abstract

摘要： 目的评估HBV感染孕期应用富马酸替诺福韦二吡呋酯(TDF)抗病毒治疗对肾功能及对胎儿生长发育的影响。方法 2018年7月1 日～2019年6月30日首都医科大学附属北京佑安医院分娩的HBV感染孕妇120例,孕期全程口服TDF治疗40例(A组),孕中晚期口服TDF治疗40例(B组),未抗病毒治疗40例(C组)。检测血清磷(P)、肾小球滤过率(GFR)、肌酐(sCr)、肌酸激酶(CK)、尿蛋白(uPRO),记录新生儿出生时头围、身长、体质量和不良事件。结果在孕36周时,A组血P、GFR、sCr、CK和uPRO分别为(1.2±0.1)mmol/L、(120.9±7.9)mL/(min·1.73 m²)、(52.1±7.9)μmol/L、(57.7±21.8)U/L、6例(15.0%),与B组【分别为(1.2±0.1)mmol/L、(119.5±9.4)mL/(min·1.73 m²)、(50.6±7.7)μmol/L、(56.6±18.8)U/L、5例(12.5%)】或C组【分别为(1.2±0.1)mmol/L、(125.7±8.7)mL/(min·1.73 m²)、(48.9±7.2)μmol/L、(53.9±16.1)U/L、4例(10.0%)】比,均无显著性差异(P>0.05);分娩时,A组孕妇新生儿身高、头围和体质量分别为(50.0±1.1)cm、(333.6±5.1)cm和(3383±319)g,与B组【分别为(49.9±1.2)cm、(333.9±5.1)cm和(3215±327)g】或C组【分别为(50.1±1.1)cm、(332.9±5.7)cm和(3284±328)g】比,均无显著性差异(P>0.05);在分娩不良事件方面,仅C组出现1例新生儿锁骨骨折。结论 TDF对HBV感染孕妇肾功能和胎儿生长发育无显著影响,母儿安全性良好。

关键词: 乙型肝炎病毒携带者, 替诺福韦酯, 孕妇, 胎儿

Abstract: Objective The aim of this study was to evaluate the safety of tenofovir disoproxil fumarate (TDF) therapy in pregnant women. Methods 120 pregnant female HBV carriers delivered in Beijing You'an Hospital, Capital Medical University,between July 1, 2018 and June 30, 2019. 40 carriers (group A) started taking TDF within one year before pregnancy until the delivery, 40 carriers (group B) taking at 24 to 28 weeks of pregnancy, and 40 carriers (group C) did not taking antiviral medicine. All pregnant women took blood and urine routine examination at the 12th and 36th weeks of pregnancy to evaluate the renal functions, such as serum phosphorus (P), glomerular filtration rate (GFR), creatinine (sCr), creatine kinase (CK) and urinary protein (uPRO). We also record the physical development indexes of newborns at birth, such as head circumference, body length and body mass. The adverse events of newborns recorded such as neonatal clavicle fracture, birth defect and neonatal death. Results At 36th week of gestation, serum P, GFR, sCr, CK and uPRO in group A were(1.2±0.1)mmol/L,(120.9±7.9)mL/(min·1.73 m²),(52.1±7.9)μmol/L, (57.7±21.8)U/L and 6 cases (15.0%) positive, in group B were (1.2±0.1)mmol/L, (119.5±9.4)mL/(min·1.73 m²), (50.6±7.7)μmol/L, (56.6±18.8)U/L and 5 cases (12.5%), and in group C were (1.2±0.1)mmol/L, (125.7±8.7)mL/(min·1.73 m²), (48.9±7.2)μmol/L, (53.9±16.1)U/L and 4 cases(10.0%), not significantly different among them (P>0.05); the height, head circumference and birth weight of newborns in group A were (50.0±1.1)cm, (333.6±5.1)cm and(3383±319)g, in group B were (49.9±1.2)cm, (333.9±5.1)cm and 3215±327)g, and in group C were (50.1±1.1) cm, (332.9±5.7)cm and(3284±328)g, not significantly different among them (P>0.05); only one neonatal had clavicular fracture in group C in our series. Conclusion TDF has no untoward effects on renal function tests and fetal growth in pregnant women with HBV infection. It might be administered safely during pregnancy.

Key words: Hepatitis B viral carriers, Tenofovir disoproxil fumarate, Pregnant women, fetus

熊霞鹂, 魏宏, 朱云霞, 段钟平. 富马酸替诺福韦二吡呋酯对HBV感染孕妇肾功能和胎儿生长发育的安全性研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 484-487.

Xiong Xiali, Wei Hong, Zhu Yunxia, et al. Safety of tenofovir disoproxil fumarate in pregnant women with HBV infection: An observation on renal functions and fetal growths[J]. Journal of Practical Hepatology, 2022, 25(4): 484-487.

参考文献

[1] Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization, 2020.
[2] Terrault NA, Levy MT, Cheung KW, et al. Viral hepatitis and pregnancy. Nat Rev Gastroenterol Hepatol,2021,18(2):117-130.
[3] Hou J, Cui F, Ding Y, et al. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus. Clin Gastroenterol Hepatol, 2019,17(10):1929-1936.
[4] Funk AL, Lu Y, Yoshida K, et al. Efficacy and safety of antiviral prophylaxis duringpregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis,2021,21(1):70-84.
[5] 中华医学会妇产科学分会产科学组,中华医学会围产医学分会.乙型肝炎病毒母婴传播预防临床指南(2020年).中华妇产科杂志,2020,55(5):291-299.
[6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[7] Nguyen MH, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev,2020,33(2): e00046-19.
[8] Aslam A, Campoverde KJ, Malladi VR, et al. Management of chronic hepatitis B during pregnancy. Gastroenterol Rep (Oxf), 2018,6(4):257-262.
[9] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017, 67(2):370-398.
[10] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018,67(4):1560-1599.
[11] Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol,2017,9(5):227-241.
[12] Wong GL, Seto WK, Wong VW,et al. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther, 2018,47(6):730-737.
[13] Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int,2018,38(1):84-89.
[14] Shang J, Liu H, Wen Q, et al. Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy. Int J Infect Dis,2021,105:626-631.
[15] Jourdain G, Harrison L, Decker L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med,2018,378(10):911-923.
[16] Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mothertoinfant transmission of hepatitis B virus. Hepatology,2015,62(2):375386.
[17] Brown RS, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology,2016,63(1):319-333.
[18] Gibb DM, Kizito H, Russell EC,et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med,2012,9(5): e1001217.
[19] Siberry GK, Jacobson DL, Kalkwarf HJ, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis,2015,61(6):996-1003.
[20] Tarantal AF, Castillo A, Ekert JE,et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr,2002,29(3):207-220.

富马酸替诺福韦二吡呋酯对HBV感染孕妇肾功能和胎儿生长发育的安全性研究^*

Safety of tenofovir disoproxil fumarate in pregnant women with HBV infection: An observation on renal functions and fetal growths

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	莫金英, 余希, 余雪平, 吴丽华, 瞿志军. FibroTouch诊断乙型肝炎病毒携带者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 480-483.
[2]	姜悦萌, 马于琪, 阚春明, 尹华发. 应用核苷(酸)类治疗慢性乙型肝炎患者早期肾功能的变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 351-354.
[3]	孙海荣, 冯伟广, 周冰清, 刘慧敏, 蒋蓓莉. 不同血清ALT水平的乙型肝炎病毒感染者肝纤维化指标变化[J]. 实用肝脏病杂志, 2021, 24(4): 488-491.
[4]	黄永群, 黄润强, 熊平安. 替诺福韦酯联合双重免疫方案阻断HBV携带孕妇母婴病毒传播效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 331-334.
[5]	韩白乙拉, 索淑一, 魏冬梅, 赵志峰, 王炳元. 替诺福韦酯与替比夫定阻断乙型肝炎病毒携带孕妇病毒母婴传播的疗效和安全性比较[J]. 实用肝脏病杂志, 2021, 24(2): 192-195.
[6]	贺宇峰, 钟晓妮, 黄建溶, 赖思奇. 替诺福韦酯与恩替卡韦治疗慢性乙型肝炎患者疗效和血清成纤维细胞生长因子-23水平变化[J]. 实用肝脏病杂志, 2021, 24(2): 200-203.
[7]	周娟, 刘月合, 王春佟. 应用替比夫定和替诺福韦治疗阻断血清HBV DNA高载量孕妇母婴传播的效果分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 805-808.
[8]	赵蕾, 李小丹, 刘淼. 拉米夫定与替比夫定阻断乙型肝炎病毒宫内感染的疗效和风险分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 496-499.
[9]	方利娟,吴雄飞. 恩替卡韦治疗乙型肝炎病毒携带者合并肺结核患者临床疗效分析[J]. 实用肝脏病杂志, 2020, 23(3): 340-343.
[10]	范凌, 杨军, 纪风兵, 周琴. 妊娠中期应用替比夫定控制乙型肝炎病毒携带孕妇病毒载量及其阻断母婴传播效果分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 179-182.
[11]	周晓旭, 张华杰, 商志娟. 速度向量成像技术定量参数评估妊娠期肝内胆汁淤积症孕妇胎儿心功能研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 62-65.
[12]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[13]	胡群凤, 杨莉. 112例妊娠期肝损害患者妊娠结局分析*[J]. 实用肝脏病杂志, 2019, 22(5): 664-667.
[14]	陈嵘, 黄美玲, 凌雪梅, 林小红, 曾俊, 黎云, 夏建红. 替比夫定联合HBIG和乙肝疫苗阻断HBV母婴传播临床效果分析*[J]. 实用肝脏病杂志, 2019, 22(5): 752-753.
[15]	杨蕊西, 刘茗心, 陈泠忻, 施剑, 瞿波. 替诺福韦酯挽救治疗HBV DNA聚合酶区204位点突变的经治慢性乙型肝炎患者疗效及安全性分析[J]. 实用肝脏病杂志, 2019, 22(3): 349-352.